References
- Kanai K, Sawai S, Sagawa K, et al. Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome. Neurology 2012;79:575–582.
- Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003;101:2496–2506.
- Dispenzieri A. POEMS syndrome. Hematology Am Soc Hematol Educ Program 2005:360–367.
- Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009;23:1716–1730.
- Zagouri F, Kastritis E, Gavriatopoulou M, et al. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Leuk Lymphoma 2014;55:2018–2023.
- Tomas JF, Giraldo P, Lecumberri R, et al. POEMS syndrome with severe neurological damage clinically recovered with lenalidomide. Haematologica 2012;97:320–322.
- Shortt J, Hsu AK, Johnstone RW. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene 2013;32:4191–4202.
- Dietrich PY, Duchosal MA. Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. Ann Oncol 2008;19:595.
- Dispenzieri A. Long-term outcomes after autologous stem cell transplantation in patients with POEMS syndrome. Clin Adv Hematol Oncol 2012;10:744–746.
- Gronier S,Delmont E,Legros L, et al.[Efficacy of autologous peripheral blood stem cell transplantation (auto-PBSCT) on the neuropathic manifestations in POEMS syndrome]. Rev Neurol (Paris) 2014;170:37–45.